Stipple Bio

We will take all space rocket imagery in biotech land … especially when we’re working on drugging novel tumor-specific epitopes to treat really difficult cancers A big congrats on the company launch and $100m series A financing to @a16z portfolio company @stipplebio! fiercebiotech.com/biotech/buoyed…

Come for the bold #cancer #biotech fundraise headline, stay for the beautiful mountain climbing analogy from @stipplebio co-founder @aaronmring Thank you @ldtimmerman for the spot-on coverage describing “epitomics” and why we are betting that it will yield novel handles (and binders) for tumor-specific biology

Proud to be featured by @a16z on why they’re investing in Stipple Bio as they share their perspective on the opportunity to unlock new targets in oncology through epitope-level precision. open.substack.com/pub/a16z/p/inv…

Today, we announced $100 million oversubscribed Series A financing to support advancement of our lead candidate, STP-100, and Pointillist Platform, designed to identify tumor-specific cell surface epitopes, enabling development of #precisiononcology medicines. bit.ly/3Q5BakV